Role of zoledronic acid in the prevention and treatment of osteoporosis

Agnès Räkel, Andrée Boucher, Louis-Georges Ste-MarieEndocrinology, Department of Medicine. Centre de recherche du CHUM, Université de Montréal, Montréal, QC, CanadaAbstract: Taken once a year, intravenous zoledronic acid (Zol) (Reclast&...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Räkel A, Boucher A, Ste-Marie L-G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Zoledronic acid osteoporosis elderly. Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/ab0974cfecea4416af1a7e6ac9610e07
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ab0974cfecea4416af1a7e6ac9610e07
record_format	dspace
spelling	oai:doaj.org-article:ab0974cfecea4416af1a7e6ac9610e072021-12-02T04:06:23ZRole of zoledronic acid in the prevention and treatment of osteoporosis1178-1998https://doaj.org/article/ab0974cfecea4416af1a7e6ac9610e072011-03-01T00:00:00Zhttps://www.dovepress.com/role-of-zoledronic-acid-in-the-prevention-and-treatment-of-osteoporosi-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Agnès Räkel, Andrée Boucher, Louis-Georges Ste-MarieEndocrinology, Department of Medicine. Centre de recherche du CHUM, Université de Montréal, Montréal, QC, CanadaAbstract: Taken once a year, intravenous zoledronic acid (Zol) (Reclast® or Aclasta®) is a third-generation nitrogen-containing bisphosphonate that is effective compared with placebo in reducing the risk of fractures in patients with postmenopausal osteoporosis and recent low-trauma hip fracture. In glucocorticoid-induced osteoporosis, there is no significant difference between Zol and risedronate for new fractures. Improvements in bone mineral density and early reduction of bone remodeling markers are observed in postmenopausal osteoporosis, recent low-trauma hip fracture, and glucocorticoid-induced osteoporosis. Given that Zol is generally well tolerated and very convenient, it is an interesting therapeutic option for aging patients who take multiple oral drugs, who have adherence or gastrointestinal tolerance issues, and who have an indication for oral bisphosphonates. Zol is not recommended for patients with severe renal impairment. Vitamin D deficiency should be corrected before the administration of Zol.Keywords: zoledronic acid, osteoporosis, elderly Räkel ABoucher ASte-Marie L-GDove Medical PressarticleZoledronic acidosteoporosiselderly.GeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 6, Pp 89-99 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Zoledronic acid osteoporosis elderly. Geriatrics RC952-954.6
spellingShingle	Zoledronic acid osteoporosis elderly. Geriatrics RC952-954.6 Räkel A Boucher A Ste-Marie L-G Role of zoledronic acid in the prevention and treatment of osteoporosis
description	Agnès Räkel, Andrée Boucher, Louis-Georges Ste-MarieEndocrinology, Department of Medicine. Centre de recherche du CHUM, Université de Montréal, Montréal, QC, CanadaAbstract: Taken once a year, intravenous zoledronic acid (Zol) (Reclast® or Aclasta®) is a third-generation nitrogen-containing bisphosphonate that is effective compared with placebo in reducing the risk of fractures in patients with postmenopausal osteoporosis and recent low-trauma hip fracture. In glucocorticoid-induced osteoporosis, there is no significant difference between Zol and risedronate for new fractures. Improvements in bone mineral density and early reduction of bone remodeling markers are observed in postmenopausal osteoporosis, recent low-trauma hip fracture, and glucocorticoid-induced osteoporosis. Given that Zol is generally well tolerated and very convenient, it is an interesting therapeutic option for aging patients who take multiple oral drugs, who have adherence or gastrointestinal tolerance issues, and who have an indication for oral bisphosphonates. Zol is not recommended for patients with severe renal impairment. Vitamin D deficiency should be corrected before the administration of Zol.Keywords: zoledronic acid, osteoporosis, elderly
format	article
author	Räkel A Boucher A Ste-Marie L-G
author_facet	Räkel A Boucher A Ste-Marie L-G
author_sort	Räkel A
title	Role of zoledronic acid in the prevention and treatment of osteoporosis
title_short	Role of zoledronic acid in the prevention and treatment of osteoporosis
title_full	Role of zoledronic acid in the prevention and treatment of osteoporosis
title_fullStr	Role of zoledronic acid in the prevention and treatment of osteoporosis
title_full_unstemmed	Role of zoledronic acid in the prevention and treatment of osteoporosis
title_sort	role of zoledronic acid in the prevention and treatment of osteoporosis
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/ab0974cfecea4416af1a7e6ac9610e07
work_keys_str_mv	AT raumlkela roleofzoledronicacidinthepreventionandtreatmentofosteoporosis AT bouchera roleofzoledronicacidinthepreventionandtreatmentofosteoporosis AT stemarielg roleofzoledronicacidinthepreventionandtreatmentofosteoporosis
_version_	1718401451796987904

Role of zoledronic acid in the prevention and treatment of osteoporosis

Ejemplares similares